These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 9122739

  • 21. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA.
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [Abstract] [Full Text] [Related]

  • 22. Topotecan in small cell lung cancer.
    Schiller JH.
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-27-S20-33. PubMed ID: 9425958
    [Abstract] [Full Text] [Related]

  • 23. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T, Vance RB, McGuire WP, Hoskins WJ, Brady M.
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
    Thigpen JT.
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
    Cabanillas F.
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
    [Abstract] [Full Text] [Related]

  • 33. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Morrissey LH, Scullin DC, Houston GA, Prasthofer EF, Gray JR, Burris HA, Greco FA.
    Cancer; 2002 May 01; 94(9):2426-33. PubMed ID: 12033195
    [Abstract] [Full Text] [Related]

  • 34. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P.
    Gynecol Oncol; 1997 Jan 01; 64(1):109-13. PubMed ID: 8995557
    [Abstract] [Full Text] [Related]

  • 35. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [Abstract] [Full Text] [Related]

  • 36. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ.
    Oncologist; 2002 Dec 01; 7 Suppl 5():3-10. PubMed ID: 12324628
    [Abstract] [Full Text] [Related]

  • 37. Achievements and unmet needs in the management of advanced ovarian cancer.
    Guarneri V, Piacentini F, Barbieri E, Conte PF.
    Gynecol Oncol; 2010 May 01; 117(2):152-8. PubMed ID: 20056266
    [Abstract] [Full Text] [Related]

  • 38. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
    Markman M.
    Semin Oncol; 1995 Jun 01; 22(3 Suppl 6):88-9. PubMed ID: 7597438
    [Abstract] [Full Text] [Related]

  • 39. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 Jun 01; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW, Song YS, Kang SB.
    J Obstet Gynaecol Res; 2010 Feb 01; 36(1):86-93. PubMed ID: 20178532
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.